2020 ASCO Virtual Direct™ Highlights
Breast
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on TNBC & HR+ MBC: Analysis & Comparison of 1st Line Options for PD-L1 +/- Cancers With(out) BRCA 1/2. Exploring the Optimal ET Agent to Combine With Palbociclib in the First-line Endocrine-sensitive Disease
FEATURING
Ian Krop
- 702 views
- July 13, 2020
- 4
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on HER2+ Neoadjuvant BC: Which Pts Are Candidates for Preoperative Systemic Therapy in Early Stage Setting? Is Therapy With Anthracyclines Inevitable? How Can We Shorten Duration Trastuzumab?
FEATURING
Reshma L. Mahtani
- 19 views
- July 13, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Adjuvant Therapy in HER2+ BC: Utilizing T-DM1 for Pts With Residual Disease vs. Extending Adjuvant Therapy With 1 yr of Neratinib vs. Adding Pertuzumab + SoC Trastuzumab - Which Option Provides Better Results?
FEATURING
Reshma L. Mahtani
- 21 views
- July 13, 2020